Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Hikma Pharmaceuticals Plc    HIK   GB00B0LCW083

Delayed Quote. Delayed  - 08/25 04:43:16 pm
2134 GBp   -4.22%
03:52p HIKMA PHARMACEU : delivers 'solid first half performance in transiti..
12:38p HIKMA PHARMACEU : H1 posts drop 38% YoY
08/24 HIKMA PHARMACEU : profit lower on reduced generics business
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Hikma Pharmaceuticals : delivers 'solid first half performance in transitional year'

share with twitter share with LinkedIn share with facebook
share via e-mail
08/25/2016 | 03:52pm CEST

Aug. 24--AMMAN -- Hikma Pharmaceuticals Plc. posted a 24 per cent increase in its earnings during the first half of the year, bringing its total revenue to $882 million, according to a company statement.

Hikma, a multinational pharmaceutical group, has recently reported its interim results for the six months ending June 30.

In addition to completing the West-Ward Columbus acquisition and making considerable progress in integrating its business, the group has also made strides in transferring Bedford Laboratories' products to its injectables manufacturing facilities and promoting strategic products in its MENA markets, according to the statement.

Hikma launched 44 products and received 182 approvals in the first six months of 2016, expanding its global product portfolio.

The group experienced double-digit growth in constant currency in Algeria and Egypt. Global injectables revenue is up 4 per cent compared with the figure recorded in H1 2015, or 5 per cent in constant currency. Also, generics revenue increased, reflecting the consolidation of four months of West-Ward Columbus.

Hikma remains focused on higher value products as well as on improving efficiency in its key markets, the group said.

Chairman and Chief Executive Officer of Hikma Said Darwazah said: "Hikma has delivered a solid first half performance in a transitional year. Our global injectables business is performing well, with revenue growth and strong profitability driven by a favourable product mix. We continue to successfully transfer the Bedford products to our injectables facilities".

In the MENA region, Hikma is expanding its market reach and is in the advanced stages of entering the Palestinian market through a partnership with Pharmacare. The partnership involves the manufacturing and distribution of an initial portfolio of products that might expand over time.


(c)2016 the Jordan Times (Amman, Jordan)

Visit the Jordan Times (Amman, Jordan) at www.jordantimes.com

Distributed by Tribune Content Agency, LLC.

© Tribune Content Agency, source Regional News

share with twitter share with LinkedIn share with facebook
share via e-mail
03:52p HIKMA PHARMACEUTICALS : delivers 'solid first half performance in transitional y..
12:38p HIKMA PHARMACEUTICALS' : H1 posts drop 38% YoY
08/24 HIKMA PHARMACEUTICALS : profit lower on reduced generics business
08/24 HIKMA PHARMACEUTICALS : post 38% drop in H1 profits
08/24 HIKMA PHARMACEUTICALS : reports 24pc increase in revenue
08/24 CORRECT : Hikma Keeps 2016 Guidance, Interim Dividend As Profit Down
08/24 TOP NEWS : Hikma Keeps 2016 Guidance, Interim Dividend As Profit Down
08/10 HIKMA PHARMACEUTICALS : *charles stanley cuts hikma pharmaceutical to 'buy' ('st..
08/10 HIKMA PHARMACEUTICALS : *goldman raises hikma pharmaceutical price target to 268..
08/08 HIKMA PHARMACEUTICALS : *barclays raises hikma pharmaceutical pt to 2900 pence -..
More news
Sector news : Pharmaceuticals - NEC
03:56pDJStocks Fall as Investors Look to Fed's Jackson Hole Meeting
03:12pDJStocks Fall as Investors Look to Fed's Jackson Hole Meeting
03:11pDJStocks Fall as Investors Look to Fed's Jackson Hole Meeting -- 3rd Update
02:15pDJMylan Boosts Price Assistance for EpiPen Amid Backlash
11:37aDJShares Fall as Health-Care Sector Loses Ground -- Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
08/24 Hikma Pharmaceuticals' (HKMPF) CEO Said Darwazah on Q2 2016 Results - Earning..
08/24 Hikma Pharmaceuticals reports H1'16 results
03/16 Hikma Pharmaceuticals' (HKMPF) CEO Said Darwazah on Q4 2015 Results - Earning..
03/16 Hikma Pharmaceuticals reports FY'15 results
2015 PREMARKET BIOTECH DIGEST : Merck Earnings, Gilead Beats Again, NantKwest Surges
Financials ($)
Sales 2016 2 052 M
EBIT 2016 367 M
Net income 2016 185 M
Debt 2016 653 M
Yield 2016 0,80%
P/E ratio 2016 34,99
P/E ratio 2017 19,61
EV / Sales 2016 3,76x
EV / Sales 2017 3,09x
Capitalization 7 051 M
More Financials
Duration : Period :
Hikma Pharmaceuticals Plc Technical Analysis Chart | HIK | GB00B0LCW083 | 4-Traders
Full-screen chart
Technical analysis trends HIKMA PHARMACEUTI...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 35,3 $
Spread / Average Target 20%
Consensus details
EPS Revisions
More Estimates Revisions
Saaid Samih Taleb Darwazah Chairman & Chief Executive Officer
Khalid Nabilsi Chief Financial Officer
Ibrahim Jalal Senior Vice President-Technical Affairs
Ragheb Al-Shakhshir Vice President-Research & Development
Michael Richard Dwyer Ashton Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON15.57%324 776
ROCHE HOLDING LTD.-11.47%217 694
NOVARTIS AG-9.45%213 882
PFIZER INC.7.87%211 206
MERCK & CO., INC.18.76%173 462
More Results